Please login to the form below

Not currently logged in
Email:
Password:

LAMA

This page shows the latest LAMA news and features for those working in and with pharma, biotech and healthcare.

The end of pharma

The end of pharma

Looking back from the future, companies that marketed, say, insulin or LAMA/LABA drugs will seems like strange historical artefacts from another age.

Latest news

  • AZ builds case for its COPD triple as it chases GSK’s Trelegy AZ builds case for its COPD triple as it chases GSK’s Trelegy

    Breztri – which combines long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid (ICS) budesonide – is playing catch-up in the market with GlaxoSmithKline’s

  • AZ prepares to file COPD triple, taking on rival GSK AZ prepares to file COPD triple, taking on rival GSK

    The KRONOS trial of PT010 – which combines long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid (ICS) budesonide – was presented at a medical congress ... triple –

  • AZ rival to GSK’s COPD drug Anoro fails head-to-head test AZ rival to GSK’s COPD drug Anoro fails head-to-head test

    The results of the AERISTO trial are a blow to AZ’s ambitions for Bevespi (glycopyrronium/formoterol fumarate) – a long-acting muscarinic agonist (LAMA)/long-acting beta agonist (LABA) combination that ... The real battleground between the two

  • AZ’s COPD triple data sets up market clash with GSK AZ’s COPD triple data sets up market clash with GSK

    AZ has reported phase III data from the KRONOS trial of its PT010 triple - combining long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid ... on LABA vilanterol,

  • EMA approves GSK’s triple COPD therapy EMA approves GSK’s triple COPD therapy

    The same indication was approved by the FDA in September, and makes Trelegy the first drug on the market to combine an ICS, LABA and long-acting muscarinic receptor antagonist (LAMA)

More from news
Approximately 3 fully matching, plus 41 partially matching documents found.

Latest Intelligence

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Collaboration - discover, develop, commercialise. 339. Theravance/ Mylan. TD-4208- a novel once-daily nebulised long-acting muscarinic antagonist (LAMA) - COPD.

  • Pharma deals in February 2015 Pharma deals in February 2015

    The co-development and marketing deal with Theravance involves TD-4208 a novel, phase 3 ready, once-daily, nebulised, long-acting muscarinic antagonist (LAMA) under development to treat COPD and other

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    2, 150. Pearl Therapeutics / AstraZeneca. Acquisition. Inhaled small molecules including PT003 fixed dose combination (LABA/ LAMA for COPD (phase III).

  • Pharma deals during June 2013 Pharma deals during June 2013

    2 agonist (LABA) and a long acting muscarinic antagonist (LAMA) is expected to become an important new class of treatment.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics